Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$693M |
| 2 |
Constellation Brands
STZ
|
+$368M |
| 3 |
Tesla
TSLA
|
+$332M |
| 4 |
NVIDIA
NVDA
|
+$300M |
| 5 |
Booking.com
BKNG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$821M |
| 2 |
Netflix
NFLX
|
+$777M |
| 3 |
AbbVie
ABBV
|
+$583M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$477M |
| 5 |
FedEx
FDX
|
+$456M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.07% |
| 2 | Consumer Discretionary | 17.72% |
| 3 | Financials | 13.25% |
| 4 | Healthcare | 11.94% |
| 5 | Communication Services | 11.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Thermo Fisher Scientific
TMO
$214B
| $33.7M | 0.03% |
162,688
+17,497
| +12% | +$3.71M |
|
327
Teradata
TDC
$2.75B
| $33.6M | 0.03% |
836,618
-3,899
| -0.5% | -$157K |
|
328
Qualcomm
QCOM
$172B
| $33.4M | 0.03% |
594,677
-971,268
| -62% | -$54.2M |
|
|
MCRN
329
DELISTED
Milacron Holdings Corp.
MCRN
| $33.1M | 0.03% |
1,747,695
+56,319
| +3% | +$1.11M |
|
|
KYNB
330
Kyntra Bio
KYNB
$28.2M
| $32.9M | 0.03% |
21,054
+8,052
| +62% | +$10.5M |
|
|
DBVT
331
DBV Technologies
DBVT
$799M
| $32.9M | 0.03% |
170,773
+24,752
| +17% | +$5.58M |
|
332
MGM Resorts International
MGM
$11.8B
| $32.1M | 0.03% |
1,106,950
-584,652
| -35% | -$18.9M |
|
333
Plains All American Pipeline
PAA
$17.2B
| $31.6M | 0.03% |
1,336,483
+213,514
| +19% | +$5.14M |
|
|
CLVS
334
DELISTED
Clovis Oncology, Inc.
CLVS
| $31.4M | 0.03% |
690,563
-7,013
| -1% | -$341K |
|
335
Byline Bancorp
BY
$1.78B
| $31.2M | 0.03% |
1,396,190
+173,074
| +14% | +$3.87M |
|
336
Enerpac Tool Group
EPAC
$1.9B
| $31.1M | 0.03% |
1,059,713
+146,290
| +16% | +$3.63M |
|
|
RVNC
337
DELISTED
Revance Therapeutics, Inc.
RVNC
| $31.1M | 0.03% |
1,131,960
-351,077
| -24% | -$10.6M |
|
338
Take-Two Interactive
TTWO
$46.3B
| $30.8M | 0.03% |
+260,578
| New | +$28.4M |
|
339
Royal Caribbean
RCL
$86.5B
| $30.7M | 0.03% |
296,585
-10,869
| -4% | -$1.19M |
|
|
EVOP
340
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $30.6M | 0.03% |
+1,485,490
| New | +$31.2M |
|
341
BlackBerry
BB
$4.74B
| $30.4M | 0.03% |
3,150,527
+1,105,890
| +54% | +$12.3M |
|
|
MRTX
342
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $30.3M | 0.03% |
614,719
+86,323
| +16% | +$3.26M |
|
343
Ameris Bancorp
ABCB
$5.9B
| $29.9M | 0.03% |
560,800
+6,928
| +1% | +$379K |
|
|
ZEN
344
DELISTED
ZENDESK INC
ZEN
| $29.8M | 0.03% |
547,257
-114,572
| -17% | -$6.09M |
|
345
Wendy's
WEN
$1.46B
| $29.7M | 0.03% |
1,728,798
-189,879
| -10% | -$3.23M |
|
|
EPZM
346
DELISTED
Epizyme, Inc
EPZM
| $29.6M | 0.03% |
2,184,788
+36,762
| +2% | +$572K |
|
347
Travere Therapeutics
TVTX
$5.2B
| $29.2M | 0.03% |
1,070,327
+14,166
| +1% | +$377K |
|
348
Olin
OLN
$2.44B
| $28.1M | 0.03% |
978,965
-238,588
| -20% | -$7.42M |
|
349
Spotify
SPOT
$105B
| $27.8M | 0.03% |
+165,408
| New | +$26.4M |
|
350
Glaukos
GKOS
$8.89B
| $27.6M | 0.03% |
678,096
+75,990
| +13% | +$2.7M |
|
Similar funds
Jennison Associates's Q2 2018 Portfolio in Review
As of Q2 2018, Jennison Associates held 740 positions worth $103B, up 2% from $101B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Jennison Associates withdrew a net $3.95B in Q2 2018, closing 87 positions and reducing 296 holdings. Its most notable exit was Great Plains Energy Incorporated, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jennison Associates opened a new position in AstraZeneca worth $677M.
- Jennison Associates's largest Q2 2018 buy was AstraZeneca: 9,637,084 shares worth $677M.
- Jennison Associates added most to Constellation Brands in Q2 2018, an estimated $368M increase.
- Jennison Associates's biggest Q2 2018 reduction was Charter Communications, cutting an estimated $821M.
- Jennison Associates fully exited Great Plains Energy Incorporated in Q2 2018, selling an estimated $152M.
- Jennison Associates's ten largest holdings make up 29% of its $103B portfolio in Q2 2018.
- Jennison Associates opened 89 new positions and closed 87 in Q2 2018.
- Jennison Associates's portfolio value rose 2% quarter-over-quarter to $103B.
Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.